REGENERX BIOPHARMACEUTICALS INC Quarterly Contract with Customer, Liability, Noncurrent in USD from Q4 2018 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
Summary
Regenerx Biopharmaceuticals Inc quarterly Contract with Customer, Liability, Noncurrent history and growth rate from Q4 2018 to Q1 2023.
  • Regenerx Biopharmaceuticals Inc Contract with Customer, Liability, Noncurrent for the quarter ending March 31, 2023 was $1.85M, a 3.98% decline year-over-year.
Contract with Customer, Liability, Noncurrent, Quarterly (USD)
Contract with Customer, Liability, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q1 2023 $1.85M -$76.8K -3.98% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $1.87M -$76.8K -3.94% Dec 31, 2022 10-Q 2023-05-15
Q3 2022 $1.89M -$76.8K -3.9% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $1.91M -$76.8K -3.87% Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $1.93M -$76.8K -3.83% Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $1.95M -$76.8K -3.79% Dec 31, 2021 10-K 2023-04-11
Q3 2021 $1.97M -$76.8K -3.76% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $1.99M -$76.8K -3.72% Jun 30, 2021 10-Q 2021-08-06
Q1 2021 $2.01M -$76.8K -3.69% Mar 31, 2021 10-Q 2021-05-14
Q4 2020 $2.02M -$76.8K -3.65% Dec 31, 2020 10-K 2022-03-30
Q3 2020 $2.04M -$76.8K -3.62% Sep 30, 2020 10-Q 2020-11-13
Q2 2020 $2.06M Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $2.08M Mar 31, 2020 10-Q 2020-05-15
Q4 2019 $2.1M -$76.8K -3.52% Dec 31, 2019 10-K 2021-03-02
Q3 2019 $2.12M Sep 30, 2019 10-Q 2019-11-14
Q4 2018 $2.18M Dec 31, 2018 10-K 2020-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.